Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare expenditures
Name
Berndt_Regional variation.pdf
Size
410.97 KB
Format
Adobe PDF
Checksum (MD5)
8f0c1374854b33d4c23549b8df28b1aa
Author(s)
Donohue, Julie M.
Normand, Sharon-Lise T.
Horvitz-Lennon, Marcela
Men, Aiju
Huskamp, Haiden A.
Berndt, Ernst R
Date Issued
June 2016
Journal
The Journal of Mental Health Policy and Economics
Publisher
Wiley Blackwell
Citation
Donohue, Julie M. et al. "Regional variation in physician adoption of antipyschotics: Impact on US Medical expenditures." The Journal of Mental Health Policy and Economics, The Journal of Mental Health Policy and Economics 19.2 (2016): 69–78.
Version
Author's final manuscript
Abstract
Background—Regional variation in US Medicare prescription drug spending is driven by higher prescribing of costly brand-name drugs in some regions. This variation likely arises from differences in the speed of diffusion of newly-approved medications. Second-generation
antipsychotics were widely adopted for treatment of severe mental illness and for several off-label uses. Rapid diffusion of new psychiatric drugs likely increases drug spending but its relationship to non-drug spending is unclear. The impact of antipsychotic diffusion on drug and medical
spending is of great interest to public payers like Medicare, which finance a majority of mental health spending in the U.S.
MIT Department
Sloan School of Management
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
http://www.icmpe.org/test1/journal/issues/v19i2toc.html
